Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Zhongguo Zhong Yao Za Zhi ; 41(6): 1100-1106, 2016 Mar.
Article in Chinese | MEDLINE | ID: mdl-28875677

ABSTRACT

To explore the effects of Shaoyao Gancao decoction on contents of amino acids and expressions of receptors in the brains of spastic paralysis rats, the spastic paralysis rat models of stroke convalescence were made by line tethering method. Baclofen was used as the control group, and the experiment group received Shaoyao Gancao decoction at 3∶1 proportions. After 3 weeks, the neurobehavioral scores, muscular tension and pain threshold were measured and compared. High performance liquid chromatography (HPLC) was used to detect the contents of GABA, Gly, Glu, Asp in cerebral cortex. The protein expressions of GABA receptors Aα1, B; NMDA receptor NR1, NR2A and NR2B in cerebral cortex were determined by immunohistochemistry assay. The results showed that the Shaoyao Gancao decoction at 3∶1 proportion could improve the spastic paralysis state after stroke, significantly improve neurological symptoms (P<0.01), decrease muscular tension (P<0.01) and improve pain threshold (P<0.05) as compared with model group. Simultaneously, the contents of inhibitory amino acids GABA and Gly were increased significantly (P<0.01), while with a decrease tendency in excitatory amino acids Glu and Asp (with no statistical significance). In addition, it could significantly increase the protein expressions of neurotransmitter GABA receptors Aα1, and B (P<0.05); reduce the expressions of neurotransmitter NMDA receptors NR1, NR2A and NR2B (P<0.05). These results suggested that the Shaoyao Gancao decoction at 3:1 proportion could effectively relieve spasm and pain. The mechanism might be associated with increasing the contents of inhibitory amino acids and increasing the expressions of their receptors in spastic paralysis rats after stroke, which would consequently enhance the signal transduction of inhibitory amino acids. Meanwhile, there was a decrease tendency in excitatory amino acids, although no significant effect was observed, and it could suppress the expressions of excitatory amino acids receptors, thus weaken the excitatory signal transduction. Thereby the neurotoxicity was relieved eventually. These findings indicated that Shaoyao Gancao decoction could regulate the balance of neurotransmitter system to relieve the spasticity, and eventually achieve tendon tonifying and spasm relieving effect.


Subject(s)
Amino Acids/metabolism , Brain/drug effects , Drugs, Chinese Herbal/administration & dosage , Muscle Spasticity/drug therapy , Paralysis/drug therapy , Receptors, N-Methyl-D-Aspartate/metabolism , Amino Acids/chemistry , Animals , Brain/metabolism , Chromatography, High Pressure Liquid , Humans , Male , Muscle Spasticity/genetics , Muscle Spasticity/metabolism , Paralysis/genetics , Paralysis/metabolism , Rats , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate/genetics
2.
Neuromuscul Disord ; 25(11): 908-12, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26494408

ABSTRACT

We report a patient with paramyotonia congenita/hyperkalemic periodic paralysis due to Nav1.4 I693T mutation who had worsening of myotonia and muscle weakness in the setting of hypomagnesemia and hypocalcemia with marked recovery after magnesium administration. Computer simulations of the effects of the I693T mutation were introduced in the muscle fiber model by both hyperpolarizing shifts in the Nav1.4 channel activation and a faster recovery from slow channel inactivation. A further shift in the Nav1.4 channel activation in the hyperpolarizing direction as expected with low divalent cations resulted in myotonia that progressed to membrane inexcitability. Shifting the channel activation in the depolarizing direction as would be anticipated from magnesium supplementation abolished the myotonia. These observations provide clinical and biophysical evidence that the muscle symptoms in sodium channelopathy are sensitive to divalent cations. Exploration of the role of magnesium administration in therapy or prophylaxis is warranted with a randomized clinical trial.


Subject(s)
Models, Biological , Myotonic Disorders/physiopathology , NAV1.4 Voltage-Gated Sodium Channel/metabolism , Paralysis/physiopathology , Adult , Cations/metabolism , Computer Simulation , Humans , Male , Muscles/cytology , Muscles/physiopathology , Myotonic Disorders/genetics , NAV1.4 Voltage-Gated Sodium Channel/genetics , Oligopeptides , Paralysis/genetics
3.
CNS Neurol Disord Drug Targets ; 14(2): 295-302, 2015.
Article in English | MEDLINE | ID: mdl-25613505

ABSTRACT

Aging is a process of progressive decline in physiological functions resulting in increased vulnerability to diseases and death. Aging results in increased rates of age related disorders like neurodegenerative diseases, cardiovascular diseases, diabetes, cancer, arthritis etc. Modulation of insulin signaling, protein aggregation, stress, free radical damage and inflammation are the major causes for deleterious changes resulting in aging. Many studies are being undertaken to find novel compounds which can improve a typical human life span and aid in healthy aging. We investigated the potential of one such compound silymarin for its anti-aging effect. Silymarin is a flavanone derivative extracted from the seeds of the milk thistle Silybum marianum. It is widely used for the treatment of liver diseases in clinical practice. We tested the anti-aging efficacy of silymarin using the Caenorhabditis elegans model system. Our results demonstrate that C. elegans treated with 25µM and 50µM silymarin concentration resulted in an increase in mean lifespan by 10.1% and 24.8% respectively compared to untreated control. Besides increased lifespan, silymarin treated aged animals showed better locomotion rate, higher response to stimuli and improved tolerance to stress compared to untreated control. We also checked the potential of silymarin to slow the progression of neurodegenerative disorder like Alzheimer's disease (AD) by using CL4176 C. elegans model for AD. C. elegans CL4176 transgenic animal induces expression of amyloid beta-protein (Aß1-42) in muscle tissues when subjected to temperature of 23°C and above resulting in worm paralysis. CL4176 animals treated with silymarin showed delayed paralysis via enhancing resistance to oxidative stress. These results suggested that silymarin is a potential hormetin for preventing aging and age-related diseases.


Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Amyloid beta-Peptides/genetics , Longevity/drug effects , Peptide Fragments/genetics , Protective Agents/therapeutic use , Silymarin/therapeutic use , Alzheimer Disease/complications , Analysis of Variance , Animals , Animals, Genetically Modified , Caenorhabditis elegans , Disease Models, Animal , Dose-Response Relationship, Drug , Humans , Movement/drug effects , Paralysis/drug therapy , Paralysis/genetics , Survival Analysis
4.
PLoS One ; 9(12): e115791, 2014.
Article in English | MEDLINE | ID: mdl-25531450

ABSTRACT

Paralysis after a spinal cord injury (SCI) induces physiological adaptations that compromise the musculoskeletal and metabolic systems. Unlike non-SCI individuals, people with spinal cord injury experience minimal muscle activity which compromises optimal glucose utilization and metabolic control. Acute or chronic muscle activity, induced through electrical stimulation, may regulate key genes that enhance oxidative metabolism in paralyzed muscle. We investigated the short and long term effects of electrically induced exercise on mRNA expression of human paralyzed muscle. We developed an exercise dose that activated the muscle for only 0.6% of the day. The short term effects were assessed 3 hours after a single dose of exercise, while the long term effects were assessed after training 5 days per week for at least one year (adherence 81%). We found a single dose of exercise regulated 117 biological pathways as compared to 35 pathways after one year of training. A single dose of electrical stimulation increased the mRNA expression of transcriptional, translational, and enzyme regulators of metabolism important to shift muscle toward an oxidative phenotype (PGC-1α, NR4A3, IFRD1, ABRA, PDK4). However, chronic training increased the mRNA expression of specific metabolic pathway genes (BRP44, BRP44L, SDHB, ACADVL), mitochondrial fission and fusion genes (MFF, MFN1, MFN2), and slow muscle fiber genes (MYH6, MYH7, MYL3, MYL2). These findings support that a dose of electrical stimulation (∼10 minutes/day) regulates metabolic gene signaling pathways in human paralyzed muscle. Regulating these pathways early after SCI may contribute to reducing diabetes in people with longstanding paralysis from SCI.


Subject(s)
Biomarkers/metabolism , Electric Stimulation Therapy , Muscle, Skeletal/pathology , Paralysis/complications , Paralysis/genetics , Spinal Cord Injuries/etiology , Spinal Cord Injuries/rehabilitation , Adaptation, Physiological/physiology , Adult , Exercise/physiology , Gene Expression Profiling , Gene Expression Regulation , Gene Regulatory Networks , Humans , Muscle, Skeletal/metabolism , Musculoskeletal Physiological Phenomena , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Spinal Cord Injuries/pathology
5.
BMJ Case Rep ; 20142014 Oct 17.
Article in English | MEDLINE | ID: mdl-25326571

ABSTRACT

Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal-dominant disorder associated with recurrent mononeuropathies following compression or trivial trauma. Reports on sciatic neuropathy as the presenting manifestation of HNPP are very scarce. We report on a 21-year-old previously healthy man who was admitted with sensorimotor deficits in his left leg. He had no history of preceding transient episodes of weakness or sensory loss. Clinical and electrophysiological examinations were consistent with sciatic neuropathy. Cerebrospinal fluid investigation and MRI of the nerve roots, plexus, and sciatic nerve did not indicate the underlying aetiology. When extended electrophysiological tests revealed multiple subclinical compression neuropathies in the upper limbs, HNPP was contemplated and eventually confirmed by genetic testing.


Subject(s)
Hereditary Sensory and Motor Neuropathy/diagnosis , Hereditary Sensory and Motor Neuropathy/genetics , Sciatic Neuropathy/genetics , Adult , Arthrogryposis/diagnosis , Arthrogryposis/genetics , Arthrogryposis/therapy , Chromosome Deletion , Diagnosis, Differential , Electric Stimulation Therapy/methods , Follow-Up Studies , Hereditary Sensory and Motor Neuropathy/therapy , Humans , Male , Nerve Compression Syndromes/diagnosis , Nerve Compression Syndromes/genetics , Nerve Compression Syndromes/therapy , Paralysis/diagnosis , Paralysis/genetics , Paralysis/therapy , Physical Therapy Modalities , Pressure , Sciatic Neuropathy/diagnosis , Sciatic Neuropathy/therapy , Young Adult
6.
Muscle Nerve ; 43(1): 65-75, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21171097

ABSTRACT

In humans, spinal cord injury (SCI) induces deleterious changes in skeletal muscle that may be prevented or reversed by electrical stimulation muscle training. The molecular mechanisms underlying muscle stimulation training remain unknown. We studied two unique SCI subjects whose right soleus received >6 years of training (30 minutes/day, 5 days/week). Training preserved torque, fatigue index, contractile speed, and cross-sectional area in the trained leg, but not the untrained leg. Training decreased 10 mRNAs required for fast-twitch contractions and mRNA that encodes for myostatin, an autocrine/paracrine hormone that inhibits muscle growth. Conversely, training increased 69 mRNAs that mediate the slow-twitch, oxidative phenotype, including PGC-1α, a transcriptional coactivator that inhibits muscle atrophy. When we discontinued right soleus training, training-induced effects diminished slowly, with some persisting for >6 months. Training of paralyzed muscle induces localized and long-lasting changes in skeletal muscle mRNA expression that improve muscle mass and function.


Subject(s)
Electric Stimulation Therapy/methods , Muscle, Skeletal/metabolism , Muscular Atrophy/genetics , Muscular Atrophy/therapy , Paralysis/genetics , RNA, Messenger/biosynthesis , Adult , Humans , Male , Muscle, Skeletal/innervation , Muscle, Skeletal/physiopathology , Muscular Atrophy/etiology , Paralysis/complications , RNA, Messenger/genetics , Spinal Cord Injuries/complications
7.
PLoS One ; 5(2): e9339, 2010 Feb 22.
Article in English | MEDLINE | ID: mdl-20179756

ABSTRACT

BACKGROUND: Proving the efficacy and corresponding mode of action of herbal supplements is a difficult challenge for evidence-based herbal therapy. A major hurdle is the complexity of herbal preparations, many of which combine multiple herbs, particularly when the combination is assumed to be vitally important to the effectiveness of the herbal therapy. This issue may be addressed through the use of contemporary methodology and validated animal models. METHODS AND PRINCIPAL FINDINGS: In this study, two commonly used traditional herbal formulas, Shi Quan Da Bu Tang (SQDB) and Huo Luo Xiao Ling Dan (HLXL) were evaluated using a survival assay and oxidative stress biomarkers in a well-established C. elegans model of aging. HLXL is an eleven herb formula modified from a top-selling traditional herbal formula for the treatment of arthritic joint pain. SQDB consists of ten herbs often used for fatigue and energy, particularly in the aged. We demonstrate here that SQDB significantly extend life span in a C. elegans model of aging. Among all individual herbs tested, two herbs Cinnamomum cassia bark (Chinese pharmaceutical name: Cinnamomi Cortex, CIN) and Panax ginseng root (Chinese pharmaceutical name: Ginseng Radix, GS) significantly extended life span in C. elegans. CIN in both SQDB and HLXL formula extended life span via modulation of multiple longevity assurance genes, including genes involved in insulin signaling and stress response pathways. All the life-span-extending herbs (SQDB, CIN and GS) also attenuated levels of H2O2 and enhanced small heat shock protein expression. Furthermore, the life span-extending herbs significantly delayed human amyloid beta (Abeta)-induced toxicity in transgenic C. elegans expressing human Abeta. CONCLUSION/SIGNIFICANCE: These results validate an invertebrate model for rapid, systematic evaluation of commonly used Chinese herbal formulations and may provide insight for designing future evidence-based herbal therapy(s).


Subject(s)
Caenorhabditis elegans/physiology , Cinnamomum aromaticum/chemistry , Drugs, Chinese Herbal/pharmacology , Longevity/drug effects , Plant Bark/chemistry , Signal Transduction/drug effects , Aging/drug effects , Amyloid beta-Peptides/genetics , Amyloid beta-Peptides/metabolism , Animals , Animals, Genetically Modified , Caenorhabditis elegans/genetics , Caenorhabditis elegans/metabolism , Caenorhabditis elegans Proteins/genetics , Caenorhabditis elegans Proteins/metabolism , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Heat-Shock Proteins/genetics , Heat-Shock Proteins/metabolism , Heat-Shock Proteins, Small/metabolism , Humans , Hydrogen Peroxide/metabolism , Microscopy, Fluorescence , Models, Animal , Oxidative Stress/drug effects , Oxidative Stress/physiology , Paralysis/genetics , Paralysis/metabolism , Paralysis/prevention & control , Receptor, Insulin/physiology , Time Factors
8.
Neurobiol Aging ; 31(6): 1055-8, 2010 Jun.
Article in English | MEDLINE | ID: mdl-18762355

ABSTRACT

Heat shock response, mediated by heat shock proteins, is a highly conserved physiological process in multicellular organisms for reestablishment of cellular homeostasis. Expression of heat shock factors and subsequent heat shock protein plays a role in protection against proteotoxicity in invertebrate and vertebrate models. Proteotoxicity due to beta-amyloid peptide (Abeta) oligomerization has been linked to the pathogenesis of Alzheimer's disease. Previously, we demonstrated that progressive paralysis induced by expression of human Abeta(1-42) in transgenic Caenorhabditis elegans was alleviated by Abeta oligomer inhibitors Ginkgo biloba extract and its constituents [Wu, Y., Wu, Z., Butko, P., Christen, Y., Lambert, M.P., Klein, W.L., Link, C.D., Luo, Y., 2006. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 26(50): 13102-13113]. In this study, we apply a protective heat shock to the transgenic C. elegans and demonstrate: (1) a delay in paralysis, (2) increased expression of small heat shock protein HSP16.2, and (3) significant reduction of Abeta oligomers in a heat shock time-dependent manner. These results suggest that transient heat shock lessens Abeta toxicity by diminishing Abeta oligomerization, which provides a link between up regulation of endogenous chaperone proteins and protection against Abeta proteotoxicity in vivo.


Subject(s)
Amyloid beta-Peptides/toxicity , Behavior, Animal/drug effects , Heat-Shock Response/physiology , Paralysis/chemically induced , Paralysis/prevention & control , Aging/physiology , Amyloid beta-Peptides/genetics , Amyloid beta-Peptides/metabolism , Animals , Animals, Genetically Modified , Antioxidants/therapeutic use , Caenorhabditis elegans , Disease Models, Animal , Ginkgo biloba , Heat-Shock Proteins/genetics , Heat-Shock Proteins/metabolism , Hot Temperature , Humans , Hydrogen Peroxide/metabolism , Molecular Weight , Paralysis/genetics , Peptide Fragments/genetics , Peptide Fragments/metabolism , Phytotherapy/methods , Plant Extracts/therapeutic use , Time Factors
9.
Neurobiol Dis ; 20(3): 943-52, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16046140

ABSTRACT

Familial amyotrophic lateral sclerosis (FALS) has been modeled in transgenic mice by introducing mutated versions of human genomic DNA encompassing the entire gene for Cu,Zn superoxide dismutase (SOD1). In this setting, the transgene is expressed throughout the body and results in mice that faithfully recapitulate many pathological and behavioral aspects of FALS. By contrast, transgenic mice made by introducing recombinant vectors, encoding cDNA genes, that target mutant SOD1 expression to motor neurons, only, or astrocytes, only, do not develop disease. Here, we report that mice transgenic for human SOD1 cDNA with the G37R mutation, driven by the mouse prion promoter, develop motor neuron disease. In this model, expression of the transgene is highest in CNS (both neurons and astrocytes) and muscle. The gene was not expressed in cells of the macrophage lineage. Although the highest expressing hemizygous transgenic mice fail to develop disease by 20 months of age, mice homozygous for the transgene show typical ALS-like phenotypes as early as 7 months of age. Spinal cords and brain stems from homozygous animals with motor neuron disease were found to contain aggregated species of mutant SOD1. The establishment of this SOD1-G37R cDNA transgenic model indicates that expression of mutant SOD1 proteins in the neuromuscular unit is sufficient to cause motor neuron disease. The expression levels required to induce disease coincide with the levels required to induce the formation of SOD1 aggregates.


Subject(s)
Amyotrophic Lateral Sclerosis/enzymology , Amyotrophic Lateral Sclerosis/genetics , Central Nervous System/enzymology , Motor Neurons/metabolism , Mutation/genetics , Superoxide Dismutase/genetics , Amyotrophic Lateral Sclerosis/physiopathology , Animals , Animals, Newborn , Astrocytes/metabolism , Astrocytes/pathology , Central Nervous System/pathology , Central Nervous System/physiopathology , DNA, Complementary/genetics , Disease Models, Animal , Genetic Predisposition to Disease/genetics , Homozygote , Humans , Inclusion Bodies/genetics , Inclusion Bodies/metabolism , Inclusion Bodies/pathology , Mice , Mice, Transgenic , Motor Neurons/pathology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscle, Skeletal/physiopathology , Neuromuscular Junction/genetics , Neuromuscular Junction/metabolism , Neuromuscular Junction/pathology , Paralysis/genetics , Paralysis/metabolism , Paralysis/physiopathology , Superoxide Dismutase/metabolism , Superoxide Dismutase-1 , Transgenes/genetics
10.
J Neurophysiol ; 93(5): 2396-405, 2005 May.
Article in English | MEDLINE | ID: mdl-15845998

ABSTRACT

The larval neuromuscular synapse of Drosophila serves as an important model for genetic and molecular analysis of synaptic development and function. Further functional characterization of this synapse, as well as adult neuromuscular synapses, will greatly enhance the impact of this model system on our understanding of synaptic transmission. Here we describe a form of short-term synaptic depression observed at larval, but not adult, neuromuscular synapses and explore the underlying mechanisms. Larval neuromuscular synapses exhibited a form of short-term depression that was strongly dependent on stimulation frequency over a narrow range of low frequencies (0.1-1 Hz). This form of synaptic depression, referred to here as low-frequency short-term depression (LF-STD), results from an activity-dependent reduction in neurotransmitter release. However, in contrast to the predictions of depletion models, the degree of depression was independent of the initial level of neurotransmitter release over a range of extracellular calcium concentrations. This conclusion was confirmed in two temperature-sensitive (TS) paralytic mutants, cacophony and shibire, which exhibit reduced neurotransmitter release resulting from conditional disruption of presynaptic calcium channels and dynamin, respectively. Higher stimulation frequencies (40 or 60 Hz) produced two components of depression that appeared to include LF-STD as well as a more conventional component of short-term depression. These findings reveal novel properties of short-term synaptic depression and suggest that complementary genetic analysis of larval and adult neuromuscular synapses will further define the in vivo mechanisms of neurotransmitter release and short-term synaptic plasticity.


Subject(s)
Mutation , Neural Inhibition/physiology , Neuromuscular Junction/physiology , Paralysis/genetics , Temperature , Animals , Calcium/pharmacology , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drosophila , Electric Stimulation/methods , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Excitatory Postsynaptic Potentials/radiation effects , Larva , Neural Inhibition/drug effects , Neural Inhibition/radiation effects , Neuromuscular Junction/drug effects , Time Factors
11.
Brain Res ; 1020(1-2): 45-52, 2004 Sep 10.
Article in English | MEDLINE | ID: mdl-15312786

ABSTRACT

Human seizure disorders are a major health concern due to the large number of affected individuals, the potentially devastating consequences of untreated seizure occurrences, and the lack of an effective treatment for all patients. Although anticonvulsants have proven very helpful in treating seizures and remain the best option available for treatment, not all afflicted individuals respond to medication and many only do so in unique drug combinations or at the cost of adverse side-effects. Therefore, new and more effective anticonvulsants are continually sought after to combat this illness. In this study, we present results which offer the possibility of using Drosophila bang-sensitive (BS) mutants as a tool to screen anticonvulsants. By feeding the BS mutants a known anticonvulsant, potassium bromide, we have demonstrated that the drug dramatically reduces the seizures of bang senseless, the most severe of the BS mutants. This methodology suggests that the Drosophila system can potentially be a powerful instrument for assaying and testing new compounds with anticonvulsant properties.


Subject(s)
Anticonvulsants/administration & dosage , Bromides/administration & dosage , Drug Evaluation, Preclinical/methods , Potassium Compounds/administration & dosage , Refractory Period, Electrophysiological/drug effects , Seizures/drug therapy , Administration, Oral , Animals , Disease Models, Animal , Drosophila , Drosophila Proteins/genetics , Electrophysiology , Mutation , Paralysis/drug therapy , Paralysis/genetics , Seizures/genetics , Species Specificity
12.
J Neurol Sci ; 81(2-3): 159-72, 1987 Nov.
Article in English | MEDLINE | ID: mdl-3694225

ABSTRACT

Five members in three generations of a family were affected by an illness that had many clinical features of the hypokalemic form of periodic paralysis (HPP). The serum potassium was either moderately reduced or normal during attacks, and there was no evidence of myotonia or cold-intolerance. All of the patients improved to a variable degree with oral potassium supplements, and 3 responded favorably to triamterene. The usually beneficial drug acetazolamide, however, invariably caused weakness in these patients, an effect previously described in only one other family with HPP. In addition, amphetamine-like sympathomimetic drugs effectively aborted or prevented paralysis in several members. Muscle biopsy in two patients revealed some unusual features, and electromyography showed myopathic potentials. There was no evidence of diabetes. The urine electrolyte concentrations during glucose tolerance tests, however, were different from those previously reported in HPP. This family may represent a variant form of HPP.


Subject(s)
Acetazolamide/therapeutic use , Hypokalemia/drug therapy , Paralysis/drug therapy , Sympathomimetics/therapeutic use , Acetazolamide/adverse effects , Adult , Female , Humans , Hypokalemia/complications , Hypokalemia/genetics , Male , Middle Aged , Muscles/enzymology , Muscles/pathology , Paralysis/etiology , Paralysis/genetics , Pedigree
13.
J Vet Intern Med ; 1(1): 45-50, 1987.
Article in English | MEDLINE | ID: mdl-3506620

ABSTRACT

Two horse farms, on which there was a high incidence of proven and suspected equine degenerative myeloencephalopathy (EDM), were studied. Symmetric ataxia and paresis, along with laryngeal adductor, cervicofacial, local cervical, and cutaneous trunci hyporeflexia, characterized the syndrome. Serum vitamin E concentration reflected a deficient state in affected and unaffected horses on both farms when compared with selected reference groups and with published values. A high incidence of the disease was evident in offspring of two particular sires on one farm. Vitamin E supplementation resulted in correction of the deficient state in most horses and was associated with a drastic reduction in the incidence of EDM on one farm from 40% to less than 10% the year following vitamin E supplementation. In addition, during the last year, the severity of signs in the few cases was dramatically reduced. This information substantiates the hypothesis that EDM is a vitamin E-responsive disorder of Equidae with a possible familial predisposition.


Subject(s)
Brain Stem/pathology , Horse Diseases/genetics , Spinal Cord Diseases/veterinary , Vitamin E Deficiency/veterinary , Animals , Ataxia/genetics , Ataxia/veterinary , Brain Diseases/drug therapy , Brain Diseases/genetics , Brain Diseases/veterinary , Female , Horses , Male , Paralysis/genetics , Paralysis/veterinary , Reflex, Abnormal/genetics , Reflex, Abnormal/veterinary , Spinal Cord Diseases/drug therapy , Spinal Cord Diseases/genetics , Vitamin E/therapeutic use , Vitamin E Deficiency/drug therapy , Vitamin E Deficiency/genetics
SELECTION OF CITATIONS
SEARCH DETAIL